POXEL — Poxel SA Share Price
Last trade - 00:00- €18.54m
- €63.38m
- €1.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.48 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -420.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 26.56 | 6.81 | 13.4 | 0.67 | 1.98 | 56.8 | 11.6 | -49.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Directors
- Pierre Legault CHM (61)
- Thomas Kuhn CEO
- Anne Renevot CFO
- Sebastien Bolze COO
- Noah Beerman EVP (54)
- Pascale Fouqueray EVP
- Elizabeth Woo SVP
- Sophie Bozec SVP
- Takashi Kaneko SVP
- David Moller CSO
- Quentin Durand OTH
- Mohammed Baluch IND
- Pascale Boissel IND
- Janice Bourque IND
- Richard Kender IND (65)
- Kumi Sato IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 6th, 2009
- Public Since
- February 6th, 2015
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 48,673,343
- Address
- Imm Le Sunway, LYON, 69007
- Web
- https://www.poxelpharma.com/
- Phone
- +33 437372010
- Auditors
- Deloitte & Associes
Latest News for POXEL
Upcoming Events for POXEL
Full Year 2024 Poxel SA Earnings Release
Q1 2025 Poxel SA Corporate Sales Release
Poxel SA Annual Shareholders Meeting
Q2 2025 Poxel SA Corporate Sales Release
Half Year 2025 Poxel SA Earnings Release
Similar to POXEL
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
As of Today at 22:42 UTC, shares in Poxel SA are trading at €0.38. This share price information is delayed by 15 minutes.
Shares in Poxel SA last closed at €0.38 and the price had moved by -38.05% over the past 365 days. In terms of relative price strength the Poxel SA share price has underperformed the FTSE Global All Cap Index by -39.14% over the past year.
The overall consensus recommendation for Poxel SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePoxel SA does not currently pay a dividend.
Poxel SA does not currently pay a dividend.
Poxel SA does not currently pay a dividend.
To buy shares in Poxel SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.38, shares in Poxel SA had a market capitalisation of €18.54m.
Here are the trading details for Poxel SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: POXEL
Based on an overall assessment of its quality, value and momentum Poxel SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Poxel SA is €3.50. That is 818.64% above the last closing price of €0.38.
Analysts covering Poxel SA currently have a consensus Earnings Per Share (EPS) forecast of €0.92 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Poxel SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +22.71%.
As of the last closing price of €0.38, shares in Poxel SA were trading +11.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Poxel SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Poxel SA's management team is headed by:
- Pierre Legault - CHM
- Thomas Kuhn - CEO
- Anne Renevot - CFO
- Sebastien Bolze - COO
- Noah Beerman - EVP
- Pascale Fouqueray - EVP
- Elizabeth Woo - SVP
- Sophie Bozec - SVP
- Takashi Kaneko - SVP
- David Moller - CSO
- Quentin Durand - OTH
- Mohammed Baluch - IND
- Pascale Boissel - IND
- Janice Bourque - IND
- Richard Kender - IND
- Kumi Sato - IND